RxDoctor Payments Data

Shay McKelvain

Family · Clovis, NMNPI 1235883422

Payments from drug & device makers

$886in general payments, 2019–2025

Across 48 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$198
  • Lilly USA, LLC$141
  • Exact Sciences$84
  • Mylan Specialty L.p.$79
  • Novo Nordisk$73
  • Pfizer$48
  • plus $262 from 9 others

What the payments were for

  • Food & beverage$886100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$886 in reported general payments places this provider in the 75th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$80,323
Medicare patients
253
Services billed
1,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$48,503
MounjaroTirzepatide27$41,723
EliquisApixaban19$29,633
JardianceEmpagliflozin20$27,551
TrulicityDulaglutide13$19,121
XareltoRivaroxaban16$12,245
Breo ElliptaFluticasone/Vilanterol13$5,488
Incruse ElliptaUmeclidinium Bromide14$5,461
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,140
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,569
NexiumEsomeprazole Magnesium12$3,247
Gabapentin144$2,557
Albuterol Sulfate HfaAlbuterol Sulfate82$2,476
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,212
Levothyroxine Sodium191$1,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$141$60,84440 claims
Novo NordiskOzempic$73$48,50344 claims
PfizerEliquis$48$29,63319 claims
AstraZenecaNexium$32$3,24712 claims
AbbVieSynthroid$198$85818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,080 family providers in New Mexico.

Other family in Clovis

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →